A Prospective, DB, Randomized, Placebo-controlled Clinical Trial of IC Infusion of Mesenchymal Precursor Cells (MPC) in the Treatment of Patients With ST-elevation Myocardial Infarction

Trial Profile

A Prospective, DB, Randomized, Placebo-controlled Clinical Trial of IC Infusion of Mesenchymal Precursor Cells (MPC) in the Treatment of Patients With ST-elevation Myocardial Infarction

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Rexlemestrocel-L (Primary)
  • Indications Myocardial infarction
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms AMICI
  • Sponsors Angioblast Systems; Mesoblast
  • Most Recent Events

    • 18 Apr 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jul 2018.
    • 13 Sep 2016 Planned End Date changed from 1 Jun 2018 to 1 Jul 2018.
    • 13 Sep 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top